A selective, high affinity 5-HT2B receptor antagonist inhibits visceral hypersensitivity in rats

被引:22
|
作者
Ohashi-Doi, K. [1 ,2 ]
Himaki, D. [2 ]
Nagao, K. [2 ]
Kawai, M. [2 ]
Gale, J. D. [3 ]
Furness, J. B.
Kurebayashi, Y. [2 ]
机构
[1] Univ Melbourne, Dept Anat & Cell Biol, Auton & Pain Lab, Parkville, Vic 3010, Australia
[2] Pfizer Global Res & Dev, Nagoya Labs, Discovery Res, Aichi, Japan
[3] Pfizer Global Res & Dev, Clin Res, Sandwich, Kent, England
来源
NEUROGASTROENTEROLOGY AND MOTILITY | 2010年 / 22卷 / 02期
关键词
5-HT2B receptor antagonist; colon; irritable bowel syndrome; serotonin; visceral hypersensitivity; IRRITABLE-BOWEL-SYNDROME; 5-HYDROXYTRYPTAMINE RECEPTORS; LONGITUDINAL MUSCLE; COLONIC DISTENSION; SEROTONIN; MODEL; DISORDERS; ARTICLE; HYPERALGESIA; SENSITIVITY;
D O I
10.1111/j.1365-2982.2009.01395.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background RS-127445 is a selective, high affinity 5-HT(2B)receptor antagonist. We investigated whether 5-HT(2B)receptor antagonists can reduce colonic visceral hypersensitivity caused by restraint stress or by proximal colonic inflammation. Methods Visceral hypersensitivity was induced in rats by either restraint stress or injection of 2, 4, 6-trinitrobenzene sulfonic acid (TNBS) into the proximal colon. Restraint stress produced a significant increase in numbers of abdominal contractions evoked by colorectal distension (CRD), measured as a quantitative index of visceral nociception in rats. Seven days after TNBS injection, the pain threshold to CRD at the non-inflamed distal colon, that was determined as the minimum pressure required to evoke abdominal cramp, was significantly decreased. The effect of RS-127445 on visceral hypersensitivity was assessed in either naive or TNBS-treated rats. Key Results Oral administration of a selective, high affinity 5-HT(2B)receptor antagonist, RS-127445, significantly inhibited visceral hypersensitivity provoked by restraint stress (35 to 74% inhibition at 1 to 10 mg kg-1). Oral RS-127445 produced a significant suppression of TNBS-induced visceral hypersensitivity (15 to 62% inhibition at 3 to 30 mg kg-1), although it was without significant effect on the visceral nociceptive threshold of naive rats. RS-127445 (1 to 30 mg kg-1, p.o.) also dose-dependently reduced the restraint stress-induced defecation in naive and TNBS-treated rats. Conclusions & Inferences These results suggest that 5-HT(2B)receptors are involved in signaling from the colon in rats in which there is visceral hypersensitivity and that a selective 5-HT(2B)receptor antagonist could have therapeutic potential for the treatment of gut disorders characterized by visceral hypersensitivity.
引用
收藏
页码:e69 / e76
页数:8
相关论文
共 50 条
  • [1] RS-127445:: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist
    Bonhaus, DW
    Flippin, LA
    Greenhouse, RJ
    Jaime, S
    Rocha, C
    Dawson, M
    Van Natta, K
    Chang, LK
    Pulido-Rios, T
    Webber, A
    Leung, E
    Eglen, RM
    Martin, GR
    BRITISH JOURNAL OF PHARMACOLOGY, 1999, 127 (05) : 1075 - 1082
  • [2] RS-127445: A selective, high-affinity, orally bioavailable 5-HT2B receptor antagonist.
    Flippin, LA
    Bonhaus, DW
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1999, 218 : U971 - U971
  • [3] The Novel 5-HT2B Receptor Antagonist, RQ-00310941, Attenuates Visceral Hypersensitivity and Abnormal Defecation in Rat Models
    Takahashi, Nobuyuki
    Inagaki, Kazuyuki
    Taniguchi, Kana
    Sakaguchi, Yoshiko
    Kawamura, Kiyoshi
    GASTROENTEROLOGY, 2011, 140 (05) : S607 - S607
  • [4] Effects of EGIS-7625, a selective and competitive 5-HT2B receptor antagonist
    Kovács, A
    Gacsályi, I
    Wellmann, J
    Schmidt, É
    Szücs, Z
    Dubreuil, V
    Nicolas, JP
    Boutin, J
    Bózsing, D
    Egyed, A
    Tihanyi, K
    Spedding, M
    Szénási, G
    CARDIOVASCULAR DRUGS AND THERAPY, 2003, 17 (5-6) : 427 - 434
  • [5] Effects of EGIS-7625, a Selective and Competitive 5-HT2B Receptor Antagonist
    Anikó Kovács
    Istvan Gacsályi
    János Wellmann
    Éva Schmidt
    Zsuzsanna Szücs
    Valérie Dubreuil
    Jean Paul Nicolas
    Jean Boutin
    Daniel Bózsing
    Andras Egyed
    Kasoly Tihanyi
    Michael Spedding
    Gábor Szénási
    Cardiovascular Drugs and Therapy, 2003, 17 : 427 - 434
  • [6] 5-HT2B receptor and impulsivity
    Bevilacqua, L.
    Doly, S.
    Kaprio, J.
    Maroteaux, L.
    Coccaro, E.
    Rose, R. J.
    Virkkunen, M.
    Goldman, D.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S218 - S218
  • [7] The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo
    Beattie, DT
    Smith, JAM
    Marquess, D
    Vickery, RG
    Armstrong, SR
    Pulido-Rios, T
    McCullough, JL
    Sandlund, C
    Richardson, C
    Mai, N
    Humphrey, PPA
    BRITISH JOURNAL OF PHARMACOLOGY, 2004, 143 (05) : 549 - 560
  • [8] New selective 5-HT2B receptor antagonists for the treatment of fibrosis
    Pettersson, Lars
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
  • [9] SB 204741 is a selective antagonist at the cloned human 5-HT2B receptor stably expressed in HEK 293 cells
    Thomas, DR
    Baxter, GS
    Carey, JE
    Gager, TL
    Gale, DG
    Holland, V
    Muir, A
    Wilson, S
    Wood, MD
    BRITISH JOURNAL OF PHARMACOLOGY, 1996, 117 : P137 - P137
  • [10] M-Chlorophenylpiperazine (mCPP) is an antagonist at the cloned human 5-HT2B receptor
    Thomas, DR
    Gager, TL
    Holland, V
    Brown, AM
    Wood, MD
    NEUROREPORT, 1996, 7 (09) : 1457 - 1460